Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  01:00 2022-12-05 am EST
3955.00 JPY   -0.30%
11/23Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
AQ
11/23Takeda Says US FDA Grants Priority Review to Its Dengue Vaccine Candidate
MT
11/22Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limited and United Nations Institute for Training and Research Strengthening Healthcare Systems to Meet Patients' Need for Plasma-Derived Therapies

09/29/2022 | 08:01am EST

United Nations Institute for Training and Research (UNITAR) and Takeda Pharmaceutical Company Limited announced a new joint initiative focused on strengthening countries' healthcare systems to meet patients' need for plasma and plasma-derived therapies. The initiative will draw on UNITAR's expertise in training and education toward the development of innovative solutions to global challenges and Takeda's deep knowledge of rare disease and the plasma ecosystem. Global demand for plasma has greatly increased over the past 20 years and is continuing to grow due to increasing numbers of patients with rare diseases being diagnosed, as well as higher standards of care and broader access to treatment globally.

This demand for life-changing and life-sustaining plasma-derived therapies far exceeds available supply, resulting in more people around the world struggling to access the treatments they need, especially in low- and middle-income countries. The overall goal of this initiative is to create a neutral, UN-based platform that will bring together experts, policymakers, patient organizations, academia, civil society and the private sector. Through increasing awareness, building partnerships and facilitating access to the latest scientific knowledge and best practices, this platform aims to support countries in finding their own tailored solutions on how to improve the quality of life and life expectancy of patients who rely on plasma-derived therapies.

The project will also focus on complementing and finding synergies with other existing initiatives to improve plasma ecosystems and increase patient access to care. The importance of plasma-derived therapies is affirmed by their inclusion in the WHO Model List of Essential Medicines1, emphasizing their significance for the healthcare system and the need to facilitate access to these products in all countries. Similarly, an increasing number of countries acknowledges the need for – and interest in – strengthening the resilience of their healthcare systems in the field of plasma supply.

Pending official confirmation, the pilot phase of the current initiative will be implemented in collaboration with two countries, whose forward-thinking participation in this program to bolster their countries' health infrastructure around plasma and the patients plasma-derived therapies can help will serve as a pathfinder for potential expansion of the project in the future. UNITAR will serve as a coordinator of the project, hosting the platform as a collaborative framework for stakeholders to meet, lead informed discussion and lay the groundwork for future collaboration.


ę S&P Capital IQ 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
11/23Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Gra..
AQ
11/23Takeda Says US FDA Grants Priority Review to Its Dengue Vaccine Candidate
MT
11/22Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Gra..
BU
11/22Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration A..
CI
11/18Takeda - Phase 3 Trial of ICLUSIG Met Primary Endpoint in Newly-Diagnosed Ph+ ALL a Set..
AQ
11/17Takeda Pharmaceutical Says Phase 3 Leukemia Drug Trial Meets Main Endpoint
MT
11/17Phase 3 Trial of ICLUSIG« (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, ..
BU
11/17Takeda Announces Phase 3 Trial of Iclusig Met Primary Endpoint in Newly-Diagnosed Ph+ A..
CI
11/16Takeda and Discovery Education Partner on New Initiative Focusing on Health Equity
AQ
11/15Big pharma not doing enough to improve drug access - analysis
RE
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 894 B 28 774 M 28 774 M
Net income 2023 324 B 2 393 M 2 393 M
Net Debt 2023 2 714 B 20 053 M 20 053 M
P/E ratio 2023 18,9x
Yield 2023 4,54%
Capitalization 6 148 B 45 433 M 45 433 M
EV / Sales 2023 2,28x
EV / Sales 2024 2,24x
Nbr of Employees 47 347
Free-Float 96,5%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 967,00 JPY
Average target price 4 529,38 JPY
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Masami Iijima Chairman
Andrew S. Plump Director, President-Research & Development
Michael E. Mendelsohn Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED26.46%45 571
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774